Exhibit
99.1
News Release
LANDAUER
LANDAUER,
INC. Reports
Fiscal
2011 FOURTH Quarter and year end Results
Results in line with Expectations; Continued
Execution of Strategic Priorities
For Further Information Contact:
Jim Polson
FTI Consulting
Phone: 312-553-6730
Email: Jim.Polson@fticonsulting.com
GLENWOOD, Ill.— December 6, 2011—Landauer,
Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation monitoring, outsourced medical physics services
and high quality medical consumable accessories, today reported financial results for its fiscal
2011 fourth quarter and year ended September 30, 2011.
Fiscal 2011 Highlights
·
Revenue increased 5.3 percent to $120.5 million.
·
Gross profit grew 4.4 percent to $72.9 million on increased revenue and product mix.
·
Operating income increased $0.3 million to $34.9 million.
·
Net income increased 3.6 percent to $24.5 million, or $2.58 per diluted share.
·
Completed acquisition of IZI Medical Products in November.
·
Announced quarterly dividend rate of $0.55 for the first fiscal quarter of fiscal 2012 in
November, providing an annual dividend rate of $2.20 consistent with 2011 levels.
·
The military issued orders totaling $14.5 million relating to the Company’s initiatives
during the fiscal year for shipments in fiscal 2012 and beyond.
“The results for this year demonstrate
the balanced approach we are taking in the pursuit of new growth opportunities and managing resources effectively to produce steadily
improving long-term performance in our core dosimetry business and new markets,” stated Bill Saxelby, President and
CEO of Landauer. “During fiscal 2011 we made significant progress against our strategic priorities and we continue to see
strong interest from the market for services that integrate our traditional occupational monitoring services with our Medical Physics
offering.”
Landauer, Inc.
Add 1
Saxelby added, “We successfully advanced
our military initiative and received orders from the U.S. military for a program totaling $14.5 million during the fiscal year,
which will be shared with our military partner. The Company’s portion of the approved funding to date is approximately $11
million. We recently completed the acquisition of IZI Medical Products, which significantly increases our product and service offering
to help customers ensure the safe utilization of radiation. The acquisition is an excellent strategic fit and expands our reach
across the radiation safety continuum.”
Saxelby concluded, “In fiscal 2012 we
look forward to executing on the significant growth opportunities in our pipeline across several areas of our business, as well
as focusing on increasing our operating efficiency. Those opportunities include:
·
Recent contract awards in the nuclear power market which continue to strengthen our position
in this market. Since our Q3 report, we have increased our market share in the nuclear power sector from 28% to 41%.
·
Continued growth within our Medical Physics segment where we generated positive operating
income for the fourth fiscal quarter.
·
Continued expansion of our military and first responder opportunities.
·
The significant opportunities associated with the recent IZI Medical Products acquisition;
and
·
Our ability and commitment to returning value to shareholders remains strong, as evidenced
by the continuation of our cash dividend program.”
Comparison of the Three Months Ended September
30, 2011 and September 30, 2010
Revenues for the fourth fiscal quarter of 2011
were $30.5 million, an increase of $1.4 million, or 5.0% compared with revenues of $29.1 million for the same quarter in fiscal
2010. The increase was contributed by the Medical Physics segment.
Cost of sales for the fourth fiscal quarter
of 2011 was $12.7 million, an increase of $0.4 million, or 3.5%, compared with cost of sales of $12.3 million for the same quarter
in fiscal 2010. The Medical Physics segment contributed an increase of $1.1 million, while the Radiation Monitoring segment decreased
$0.6 million. Gross margins were 58.3% for the fourth fiscal quarter of 2011, compared with 57.6% for the same period in fiscal
2010.
Selling, general and administrative costs for
the fourth fiscal quarter of 2011 were $9.5 million, an increase of $0.6 million, or 6.3%, compared with the $8.9 million reported
for the fourth fiscal quarter of 2010. The increase of $0.6 million occurred in the Radiation Monitoring segment.
Operating income for the fourth fiscal quarter
of 2011 was $7.0 million, a decline of $0.5 million, or 5.9%, compared with operating income of $7.5 million for the same quarter
in fiscal 2010. For the fourth fiscal quarter of 2011, the Medical Physics segment had operating income of $0.1 million, an increase
of $0.4 million, compared to an operating loss of $0.3 million for the fourth fiscal quarter of 2010. The Radiation Monitoring
segment had operating income for the fourth fiscal quarter of 2011 of $6.9 million, a decrease of $0.9 million, or 11.4%, compared
to $7.8 million for the fourth fiscal quarter of 2010.
Net other income, including equity in income
of joint ventures, for the fourth fiscal quarter of 2011 was $0.2 million compared to $0.3 million in the prior year quarter.
The effective tax rate for the fourth fiscal
quarter of fiscal 2011 and 2010 was 25.3% and 39.7%, respectively. The decrease in effective tax rate was due primarily to the
reduction in the Company’s state taxes and the allowance of certain tax credits that had been previously disallowed.
Landauer, Inc.
Add 2
Net income for the fourth fiscal quarter ended
September 30, 2011 was $5.2 million, an increase of $0.6 million, or 13.8%, compared with $4.6 million for the fourth fiscal quarter
of 2010. The resulting diluted earnings per share for the fourth fiscal quarter of 2011 were $0.54 compared with $0.48 for the
fourth fiscal quarter of 2010.
Radiation Monitoring Segment:
Radiation Monitoring revenue for the fourth
fiscal quarter of 2011 was $24.6 million, which was the same as for the fourth fiscal quarter of 2010. Domestic Radiation Monitoring
revenue decreased 5.6%, or $1.0 million, and international Radiation Monitoring revenue increased 16.8%, or $1.0 million.
Radiation Monitoring gross margin for the fourth
fiscal quarter of 2011 increased to 66.2% from 63.7% in the fourth fiscal quarter of 2010. Selling, general and administrative
costs in the Radiation Monitoring segment for the fourth fiscal quarter of 2011 increased 8.0%, or $0.6 million, to $8.1 million.
The increase is due primarily to an additional $0.7 million of bonus expense and $0.2 million of additional costs to support international
growth, partially offset by declines in other miscellaneous expenses. Acquisition and reorganization costs for the fourth fiscal
quarter of 2011 increased by $0.9 million to $1.3 million, compared to $0.4 million for the fourth fiscal quarter of 2010. Radiation
Monitoring operating income, inclusive of the impact of acquisition related transaction and reorganization costs, for the fourth
fiscal quarter of 2011 decreased 11.4%, or $0.9 million, to $6.9 million compared with operating income of $7.8 million for the
same period in fiscal 2010.
Medical Physics Segment:
Medical Physics revenue for the fourth fiscal
quarter of 2011 increased 32.6%, or $1.5 million from the fourth fiscal quarter of 2010, to $6.0 million on $0.9 million of organic
growth and $0.6 million due to the impact of acquired companies. Medical Physics gross margin increased to 25.3% from 24.4% in
the fourth fiscal quarter of 2010 due to elimination of a non-recurring operating loss within certain Medical Physics business
in the fourth fiscal quarter of 2010 prior to divestiture of the business in the first fiscal quarter of 2011, as well as improved
operating efficiencies in the therapy physics business. Selling, general and administrative costs in the Medical Physics segment
of $1.4 million for the fourth fiscal quarter of 2011 were comparable to costs for the same period in fiscal 2010. Medical Physics
operating income for the fourth fiscal quarter of 2011 was $0.1 million, an increase of $0.4 million, compared to an operating
loss of $0.3 million for the fourth fiscal quarter of 2010.
Comparison of the Twelve Months Ended September
30, 2011 and September 30, 2010
Revenues for fiscal 2011 were $120.5 million,
an increase of $6.1 million, or 5.3%, compared with revenues of $114.4 million for fiscal 2010. The Medical Physics segment contributed
an increase of $6.6 million, offset by a decline in the Radiation Monitoring segment of $0.5 million.
Cost of sales for fiscal 2011 was $47.5 million,
an increase of $3.0 million, or 6.8%, compared with cost of sales of $44.5 million for fiscal 2010. The Medical Physics segment
contributed an increase of $5.1 million, offset by a decline in the Radiation Monitoring segment of $2.1 million. Gross margins
were 60.6% for fiscal 2011, compared with 61.1% for fiscal 2010. The decline in gross margin rate was primarily due to the overall
growth of the Medical Physics segment, which has lower margins.
Selling, general and administrative costs for
fiscal 2011 were $36.6 million, an increase of $3.4 million, or 10.1%, compared with the $33.2 million reported for fiscal 2010.
The Medical Physics segment and Radiation Monitoring segment contributed an increase of $1.1 million and $2.3 million, respectively.
The Medical Physics increase is due to the impact of acquired companies and costs to support organic growth. The Radiation Monitoring
increase is due primarily to increased international spending to support international revenue growth and the strengthening of
most foreign currencies against the dollar.
Landauer, Inc.
Add 3
In conjunction with the Company’s acquisition
activity, the Company incurred $1.5 million ($1.0 million, after tax) and $2.0 million ($1.6 million, after-tax) of acquisition
related transaction and reorganization costs for fiscal 2011 and 2010, respectively.
Operating income for the twelve months ended
September 30, 2011 was $34.9 million, an increase of $0.3 million, or 0.7%, compared with operating income of $34.6 million for
fiscal 2010. For fiscal 2011, the Medical Physics segment had an operating loss of $0.5 million, an improvement of $0.4 million
compared to an operating loss of $0.9 million for fiscal 2010. The Radiation Monitoring segment had operating income of $35.4 million,
compared to operating income of $35.6 million for fiscal 2010.
Net other income, including equity in income
of joint ventures, for fiscal 2011 was $1.9 million, an increase of $0.5 million, or 32.7%, from the prior year, due to Nagase-Landauer,
the Company’s joint venture in Japan, experiencing increased revenue in support of the Japanese nuclear disaster and a reduction
in product costs as a result of manufacturing efficiencies in its state of the art manufacturing facility which began operating
in April 2010.
The effective tax rate was 31.4% and 33.0%
for fiscal 2011 and 2010, respectively. The decrease in effective tax rate was due primarily to the reduction of nondeductible
acquisition costs as compared to fiscal 2010 and an increased research and development credit in fiscal 2011.
Net income for the twelve months ended September
30, 2011 was $24.5 million, an increase of $0.8 million, or 3.6%, compared with $23.7 million for the twelve months ended September
30, 2010. The resulting diluted earnings per share for fiscal 2011 were $2.58 compared with $2.52 for fiscal 2010.
Earnings before interest, taxes, depreciation
and amortization (“EBITDA”) were $44.4 million, a $2.0 million or 4.8% increase, compared with $42.4 million for the
prior fiscal year. The increase is due primarily to a $0.8 million increase in net income and a $1.3 million increase in depreciation
and amortization expense for fiscal 2011. A reconciliation of net income to EBITDA is included in the attached financial exhibits.
Radiation Monitoring Segment:
Radiation Monitoring revenue for fiscal 2011
declined 0.5%, or $0.5 million to $99.9 million. Of the decline, $1.6 million is due to the change in the supply relationship between
Landauer and Nagase-Landauer, the Company’s unconsolidated joint venture in Japan. Fiscal 2010 revenue included sales to
Nagase-Landauer, Ltd. of $2.5 million for badges and services to support its fiscal 2010 transition of the Japanese service market
from the Luxel badge to a next generation badge based upon the InLight platform. With the completion of the transition in the third
fiscal quarter of 2010, the joint venture only purchases service badges to support service business growth. The historical Luxel
badge revenues were partially replaced by a royalty arrangement, resulting in no corresponding impact on net income. Without the
Nagase-Landauer impact, domestic Radiation Monitoring revenue declined 3.3%, or $2.4 million, driven by lower non-recurring InLight
equipment sales, primarily to the Canadian government agency responsible for occupational monitoring and radiation emergency preparedness
for the citizens of Canada. International Radiation Monitoring revenue increased 13.9%, or $3.6 million, on $2.2 million of organic
growth in most regions and $1.6 million from the strengthening of most foreign currencies against the dollar.
Landauer, Inc.
Add 4
Radiation Monitoring gross margin for the twelve
months ended September 30, 2011 increased to 68.2% from 66.3% a year ago, primarily due to the decline in lower margin sales to
Nagase-Landauer. Selling, general and administrative costs in the Radiation Monitoring segment for fiscal 2011 increased 8.0%,
or $2.3 million, to $31.2 million. The increase is due primarily to an additional $0.2 million of costs to replace the Company’s
IT systems and related depreciation, $1.0 million of increased international spending to support international revenue growth and
$0.5 million from the strengthening of most foreign currencies against the dollar. Acquisition and reorganization costs for fiscal
2011 decreased 26.6%, or $0.5 million, to $1.5 million compared to $2.0 million in fiscal 2010. Radiation Monitoring operating
income, inclusive of the impact of acquisition related transaction and reorganization costs, for the twelve months ended September
30, 2011 decreased 0.5%, or $0.2 million, to $35.4 million compared with operating income of $35.6 million for fiscal 2010.
Medical Physics Segment:
Medical Physics revenue for 2011 increased
46.7%, or $6.6 million, to $20.6 million on $3.2 million of organic growth and $3.4 million due to the impact of acquired companies.
Medical Physics gross margin declined to 23.7% from 24.3% in the year ago period due to divestiture of the certain higher margin
business in the first fiscal quarter of 2011, and due to non-recurring expense in fiscal 2011 for workforce realignment, partially
offset by improved operating efficiencies in the core Medical Physics business. Selling, general and administrative costs in the
Medical Physics segment for fiscal 2011 increased 24.0%, or $1.1 million, to $5.4 million. The increase is due to the impact of
acquired companies and costs to support organic growth. Medical Physics operating loss was $0.5 million for fiscal 2011, compared
with operating loss of $0.9 million for fiscal 2010.
Solid
Financial Position
Landauer
ended the fourth fiscal quarter of 2011 with total assets of $169 million, an increase of $18 million compared to total assets
of $151 million at the end of fiscal year 2010. Due to the current liability classification of $19.8 million in outstanding borrowings
incurred to support the acquisitions completed during the first fiscal quarter of 2010 and thereafter, the Company had negative
working capital of $7.3 million. The Company believes projected operating cash flow and available borrowing under its current credit
arrangements provide adequate liquidity to meet its current and anticipated obligations. Cash provided by operating activities
for fiscal year ended September 30, 2011 was $31.2 million, an increase of $5.0 million
from fiscal 2010, due primarily to an increase in deferred contract revenue
and changes in the other components of working capital.
Dividend Policy
The Company also announced on November 14,
2011 that its Board of Directors has declared a regular quarterly cash dividend of $0.55 per share for the first quarter of fiscal
2012. This represents an annual rate of $2.20 per share, consistent with fiscal 2011 levels. The dividend will be paid on January
4, 2012 to shareholders of record on December 9, 2011.
Landauer, Inc.
Add 5
Fiscal
2012 Outlook
Landauer’s
business plan for fiscal 2012 currently anticipates aggregate revenue for the year to be in the range of $150 to $157 million,
which includes 10 months of contributions from the recent IZI Medical Products acquisition. The business plan also anticipates:
·
$4.4 million ($2.9 million net of tax) of non-recurring expense spending to support the successful
completion of the Company’s systems initiative and the related post implementation support.
·
Incremental depreciation and amortization over fiscal 2011 of $1.8 million ($1.2 million net
of tax) related to the deployment of the final phase of the Company’s systems initiative in the third fiscal quarter of fiscal
2012.
·
The accretive impact of the November 2011 acquisition of IZI Medical Products producing $1.1
million to $1.5 million of net income for the 10 months included in fiscal 2012.
Based
upon the above assumptions, the Company anticipates reported net income for fiscal 2012 in the range of $21 to $23 million and
EBITDA in the range of $49 to $51 million. In addition to the $5 to $7 million increase in EBITDA expected for fiscal 2012, the
Company will begin to receive an annual cash benefit of approximately $2 million as a result of the structure of the acquisition
of IZI Medical Products in November 2011.
Conference Call Details
Landauer has scheduled its fourth quarter conference
call for investors over the Internet on Tuesday, December 6, 2011 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). To
participate, callers should dial 877-941-9205 (within the United States and Canada), or 480-629-9692 (international callers) about
10 minutes before the presentation. To listen to a webcast on the Internet, please go to the Company’s website at http://www.landauerinc.com
at least 15 minutes early to register, download and install any necessary audio software. Investors may access a replay of
the call by dialing 800-406-7325 (within the United States and Canada), or 303-590-3030 (international callers), passcode 4490815#,
which will be available until January 6, 2012. The replay of the call will remain available on Landauer’s website for
90 days.
About Landauer
Landauer is a leading global provider of technical
and analytical services to determine occupational and environmental radiation exposure and is the leading domestic provider of
outsourced medical physics services. For more than 50 years, the Company has provided complete radiation dosimetry services to
hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation
poses a potential threat to employees. Landauer’s services include the manufacture of various types of radiation detection
monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings.
The Company provides its dosimetry services to approximately 1.7 million individuals globally. In addition, through its Global
Physics Solutions subsidiary, the Company provides therapeutic and imaging physics services to the medical physics community. Through
its IZI Medical Products subsidiary, the Company provides medical consumable accessories used in radiology, radiation therapy,
and image guided surgery procedures.
Landauer, Inc.
Add 6
Safe Harbor Statement
Some of the information shared here (including,
in particular, the section titled “Fiscal 2012 Outlook” constitutes forward-looking statements that are based on assumptions
and involve certain risks and uncertainties that could cause actual results to differ materially from either historical or anticipated
results depending on a variety of factors. These factors include the following, without limitation: assumptions, risks and uncertainties
associated with the Company’s future performance, the Company’s development and introduction of new technologies in
general; the ability to protect and utilize the Company’s intellectual property; continued customer acceptance of the InLight
technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; military and other
government funding for the purchase of certain of the Company’s equipment and services; the impact on sales and pricing of
certain customer group purchasing arrangements; changes in spending or reimbursement for medical products or services; the costs
associated with the Company’s research and business development efforts; the usefulness of older technologies and related
licenses and intellectual property; the effectiveness of and costs associated with the Company’s IT platform enhancements;
the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company’s long-lived
assets or business units relative to future cash flows; changes in pricing of products and services; changes in postal and delivery
practices; the Company’s business plans; anticipated revenue and cost growth; the ability to integrate the operations of
acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally;
costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing
economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term
financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations;
accreditation requirements; changes in the trading market that affect the cost of obligations under the Company’s benefit
plans; and pending accounting pronouncements. These assumptions may not materialize to the extent assumed, and risks and uncertainties
may cause actual results to be different from what is anticipated today. These risks and uncertainties also may result in changes
to the Company’s business plans and prospects, and could create the need from time to time to write down the value of assets
or otherwise cause the Company to incur unanticipated expenses. Additional information may be obtained by reviewing the information
set forth in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended September 30,
2010, and other reports filed by the Company from time to time with the Securities and Exchange Commission. The Company does not
undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future
events or changes in the Company’s expectations, except as required by law.
Financial Tables Follow
Landauer, Inc.
Add 7
Fourth Fiscal Quarter 2011 Financial Highlights
(unaudited, amounts in thousands, except
per share data)
| |
Three Months Ended
September 30, |
|
Twelve Months Ended
September 30, |
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net revenues |
$ |
30,535 |
|
$ |
29,072 |
|
$ |
120,458 |
|
$ |
114,367 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
| Cost of sales |
|
12,746 |
|
|
12,315 |
|
|
47,510 |
|
|
44,478 |
| Selling, general and administrative |
|
9,486 |
|
|
8,927 |
|
|
36,576 |
|
|
33,224 |
| Acquisition and reorganization costs |
|
1,259 |
|
|
345 |
|
|
1,489 |
|
|
2,028 |
| Cost and expenses |
|
23,491 |
|
|
21,587 |
|
|
85,575 |
|
|
79,730 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Operating income |
|
7,044 |
|
|
7,485 |
|
|
34,883 |
|
|
34,637 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Other income, net |
|
185 |
|
|
298 |
|
|
1,852 |
|
|
1,396 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Income before taxes |
|
7,229 |
|
|
7,783 |
|
|
36,735 |
|
|
36,033 |
| Income taxes |
|
1,829 |
|
|
3,087 |
|
|
11,527 |
|
|
11,893 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net income |
|
5,400 |
|
|
4,696 |
|
|
25,208 |
|
|
24,140 |
|
Less: Net income attributed to
noncontrolling interest |
|
214 |
|
|
140 |
|
|
670 |
|
|
466 |
| Net income attributed to Landauer, Inc. |
$ |
5,186 |
|
$ |
4,556 |
|
$ |
24,538 |
|
$ |
23,674 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net income per share attributable to Landauer, Inc. shareholders: |
|
|
|
|
|
|
|
|
|
|
|
| Basic |
$ |
0.55 |
|
$ |
0.49 |
|
$ |
2.60 |
|
$ |
2.53 |
|
Weighted average basic
shares
outstanding |
|
9,394 |
|
|
9,331 |
|
|
9,395 |
|
|
9,310 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Diluted |
$ |
0.54 |
|
$ |
0.48 |
|
$ |
2.58 |
|
$ |
2.52 |
|
Weighted average diluted
shares
outstanding |
|
9,477 |
|
|
9,371 |
|
|
9,477 |
|
|
9,349 |
Landauer, Inc
Add 8
Summary
Consolidated Balance Sheets
(unaudited, amounts in thousands)
| |
|
September 30,
2011 |
|
|
September 30,
2010 |
| ASSETS |
|
|
|
|
|
| Current Assets: |
|
|
|
|
|
| Cash and cash equivalents |
$ |
7,914 |
|
$ |
7,659 |
| Receivables, net of allowances |
|
25,516 |
|
|
23,702 |
| Other current assets |
|
17,212 |
|
|
14,796 |
| Total current assets |
|
50,642 |
|
|
46,157 |
| |
|
|
|
|
|
| Net property, plant and equipment |
|
47,641 |
|
|
39,815 |
| Equity in joint ventures |
|
10,699 |
|
|
8,446 |
| Goodwill and other intangible assets, net of amortization |
|
50,870 |
|
|
49,270 |
| Dosimetry devices, net of depreciation |
|
5,618 |
|
|
5,569 |
| Other assets |
|
3,186 |
|
|
1,439 |
| |
|
|
|
|
|
| TOTAL ASSETS |
$ |
168,656 |
|
$ |
150,696 |
| |
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
| Current Liabilities: |
|
|
|
|
|
| Accounts payable |
$ |
5,457 |
|
$ |
7,180 |
| Dividends payable |
|
5,301 |
|
|
5,143 |
| Deferred contract revenue |
|
14,713 |
|
|
14,305 |
| Short-term debt |
|
19,805 |
|
|
12,504 |
| Other current liabilities |
|
12,673 |
|
|
10,420 |
| Total current liabilities |
|
57,949 |
|
|
49,552 |
| |
|
|
|
|
|
| Non-Current Liabilities: |
|
|
|
|
|
| Pension and postretirement obligations |
|
14,202 |
|
|
10,089 |
| Deferred income taxes |
|
12,805 |
|
|
9,934 |
| Other non-current liabilities |
|
1,292 |
|
|
1,418 |
| Total non-current liabilities |
|
28,299 |
|
|
21,441 |
| |
|
|
|
|
|
| Stockholders’ Equity: |
|
|
|
|
|
| Landauer, Inc. stockholders’ equity |
|
81,332 |
|
|
78,790 |
| Noncontrolling interest |
|
1,076 |
|
|
913 |
| Total stockholders’ equity |
|
82,408 |
|
|
79,703 |
| |
|
|
|
|
|
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
$ |
168,656 |
|
$ |
150,696 |
Landauer, Inc
Add 9
Reconciliation
of Net Income to
Earnings before Interest, Taxes, Depreciation
and Amortization
(unaudited,
amounts in thousands)
| |
Three Months Ended
September 30, |
|
Twelve Months Ended
September 30, |
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Net income attributed to Landauer, Inc. |
$ |
5,186 |
|
$ |
4,556 |
|
$ |
24,538 |
|
$ |
23,674 |
| |
|
|
|
|
|
|
|
|
|
|
|
| Add back: |
|
|
|
|
|
|
|
|
|
|
|
| Interest and other expense (income) |
|
305 |
|
|
(21) |
|
|
339 |
|
|
105 |
| Income taxes |
|
1,829 |
|
|
3,087 |
|
|
11,527 |
|
|
11,893 |
| Depreciation and amortization |
|
2,241 |
|
|
1,946 |
|
|
7,991 |
|
|
6,681 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before interest, taxes,
depreciation and amortization |
$ |
9,561 |
|
$ |
9,568 |
|
$ |
44,395 |
|
$ |
42,353 |
Use of Non-GAAP Financial Measures
In evaluating the Company’s financial performance and outlook, management uses EBITDA. EBITDA is a non-GAAP measure. Management
believes that such measure supplements evaluations using operating income, net income, and diluted earnings per share and other
GAAP measures, and is a useful indicator for investors. This indicator can help readers gain a meaningful understanding of our
core operating results and future prospects without the effect of non-cash items and the Company’s ability to generate cash
flows from operations that are available for taxes, capital expenditures, and debt repayment. Investors should recognize that these
non-GAAP measures might not be comparable to similarly titled measures of other companies. These measures should be considered
in addition to, and not as a substitute for or superior to, any measure of performance, cash flows or liquidity prepared in accordance
with accounting principles generally accepted in the United States.
# # #
